Emergency physician Professor Charles Pollack tells us how the availability of idarucizumab (‘Praxbind’) has changed the way he manages patients who are anticoagulated with dabigatran in emergency situations.
Sponsored by Boehringer Ingelheim Pty Ltd
Emergency physician Professor Charles Pollack tells us how the availability of idarucizumab (‘Praxbind’) has changed the way he manages patients who are anticoagulated with dabigatran in emergency situations.